

## The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 23 May 2023, regarding the number and election of members of the board of directors.

The nomination committee proposes seven members of the board of directors and no deputy members of the board of directors.

The nomination committee proposes re-election of Erika Kjellberg Eriksson, Hans Johansson, Mats Nilsson, Mario Gualano and Nina Korfu-Pedersen as members of the board of directors, and election of Karin Fischer and Finn Albrechtsen for a term of office until the end of the next annual general meeting. Furthermore, the nomination committee proposes re-election of Erika Kjellberg Eriksson as chairman and election of Mario Gualano as vice chairman of the board.

Board members Per-Olof Wallström and Marianne Hansson have informed the nomination committee that they are not available for re-election to the board of directors.

Karin Fischer, born in 1976, is currently CEO of Biolin Scientific AB, a company within the AddLife group. Karin has more than 15 years of global commercial experience from both strategic and operational positions. She has also been stationed in the USA. Karin has worked in various global roles for companies such as Johnson & Johnson, Getinge, Xvivo Perfusion and RLS Global. For the latter, Karin was CEO for just over four years. RLS is listed on First North, Nasdaq. Karin has a Master's degree in economics from the University of Aberdeen, Scotland. Karin is independent in relation to the company, the company management and the company's major shareholders. She does not own any shares in the Company.

Finn Sander Albrechtsen, born in 1967, is the current CEO of Vidya Holding Ltd., and has more than 16 years of international leadership experience from the life science and diagnostics industry. This includes seven years with Dako and Agilent Technologies in roles focused on product development, from portfolio and project management to leading the global R&D function. Between 2015 and 2021, Finn was VP of R&D and Business Development for the Microbiology Division at Thermo Fisher Scientific. Finn is an engineer from the Technical University of Denmark. Finn is independent in relation to the company, the company management and the company's major shareholders. He does not own any shares in the Company.

Information about all the members proposed to Q-linea's board, the nomination committee's reasoned statement regarding the proposal to the board and the nomination committee's complete proposal will be available on the company's website, [www.qlinea.com](http://www.qlinea.com) in connection with the issue of the notice to the 2023 annual general meeting, which is expected to take place during the week 17.

The nomination committee has been appointed according to the principles decided by the 2022 annual general meeting and consists of Oscar Bergman (Swedbank Robur Fonder AB), chairman of the nomination committee, Erika Kjellberg Eriksson (Nexttobe AB, chairman of the board) and Öystein Engebretsen (Investment AB Öresund).

**For more information, please contact:**

Jonas Jarvius, CEO, Q-linea AB  
[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)  
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB  
[Anders.Lundin@qlinea.com](mailto:Anders.Lundin@qlinea.com)  
+46 (0) 70-600 15 20

**About Q-linea**

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

**Attachments**

[The proposal by the nomination committee of Q-linea AB \(publ\) for election of members of the board of directors](#)